Is GlaxoSmithKline plc still a strong buy after Q3 results?

Bilaal Mohamed shares his views on today’s third-quarter results from GlaxoSmithKline plc (LON:GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has long been a favourite with investors both great and small. Everyone from multi-billion pound fund managers to the granny next door seems to have the global pharmaceuticals giant in their portfolio, and it’s not difficult to see why.

Get-rich-quick schemes

In an age of short-termism and get rich quick schemes, sensible investors know that the first step in generating sustainable long-term wealth lies in capital preservation. It’s for this reason that companies like Glaxo often form part of the core of many well-balanced portfolios, helping to steady the ship in times of political and economic uncertainty.

Along with other defensive sectors such as consumer goods and utilities, multinational pharmaceuticals are less likely to be affected by unforeseen events such as Brexit, or a surprise election win by Donald Trump. Both equity markets and currency markets can collapse and bounce back at a moment’s notice, but these sectors are generally less sensitive to or volatile on the back of such unpredictable political events.

Income investors in particular have had a long-term love affair with Glaxo. Thanks to its capacity to generate enormous profits from worldwide sales each year, the FTSE 100 stalwart can afford to reward its shareholders with generous quarterly payouts that have helped to support the company’s share price through a period when patent expiries have led to increased levels of generic competition for some of its treatments. But what about the future? Is there any hope of growth in such a competitive market?

New York, New York

Commentators like myself had to wait until noon today to get a glimpse of Glaxo’s third-quarter results, rather than the usual 7am regulatory news releases we’re accustomed to here in the UK. The reason? Glaxo is also traded on the New York Stock Exchange (NYSE), and noon equates to 7am Eastern Time. Further proof if it were needed that Glaxo is a true pharmaceutical goliath revered on both sides of the Atlantic.

Today’s results showed continued progress during the third quarter of 2017, with growth in sales and improved operating margins. This was driven by targeted cost savings and restructuring and integration benefits, which in particular helped the Vaccines and Consumer Healthcare businesses, and also supported investment in its new products and Research & Development pipeline. There were also major approvals for its Trelegy Ellipta treatment for Chronic Obstructive Pulmonary Disease (COPD) and shingles vaccine Shingrix.

New product sales up 44%

Pharmaceutical sales were up 3% during the quarter, reflecting continued strong growth of new Respiratory and HIV products, partly offset by a decline in the older products and the impact of recent divestments. Vaccine sales were up 5%, with a strong performance from Meningitis vaccines and continued delivery from influenza products. Consumer Healthcare sales were up 5%, reflecting strong performances from power brands in the Pain and Oral health categories.

But for me, what was most encouraging of all was that sales of new pharmaceutical and vaccine products were up by an impressive 44% to £1.7bn, with total group turnover rising 4% year-on-year to a mammoth £7.8bn.

So is Glaxo still a strong buy after third-quarter results? With its defensive qualities, attractive valuation at less than 14 times forward earnings, and juicy 5.3% yield, the answer has to be a resounding YES.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

Could Raspberry Pi shares hit £5 by 2030?

After a strong start out of the blocks this month, our writer asks whether Raspberry Pi shares could move further…

Read more »

Close-up of British bank notes
Investing Articles

Five 5%+ yielders I’d buy for an ISA today!

Our writer identifies a handful of FTSE 100 and FTSE 250 firms each yielding at least 5% he'd happily buy…

Read more »

Front view photo of a woman using digital tablet in London
Investing Articles

5 stocks with 5%+ yields I’d love to buy and hold in a Stocks and Shares ISA

Harvey Jones is keen to add these five FTSE 100 high-yielders to his Stocks and Shares ISA, ideally before they…

Read more »

A young Asian woman holding up her index finger
Investing Articles

I’d target £880 of passive income annually, spending £10K now on this FTSE 100 share

Our writer explains how he would add to his diversified portfolio happily by investing in this FTSE 100 passive income…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

3 reasons I think the Scottish Mortgage share price could keep rising

Christopher Ruane explains a trio of reasons he thinks the once-mighty Scottish Mortgage share price could be set to increase…

Read more »

Syringe and vial on blue background
Investing Articles

Is this forgotten FTSE share about to make investors rich all over again?

Not long ago, this FTSE share was all the rage before demand dropped off and things went south. Is it…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

I’d use these 5 Warren Buffett approaches to build wealth

Christopher Ruane outlines a handful of investing lessons from billionaire Warren Buffett that he thinks can help a small investor…

Read more »

US Stock

Nvidia stock: 3 things investors need to know as it surges towards $150

Nvidia is a stock that's had an extraordinary run in 2024. Edward Sheldon highlights some important things investors should know.

Read more »